CLDN1 and ovarian carcinoma: CLDN1 has oncogenic activity in colon cancer [13], bladder cancer [14], lung cancer [15], gastric cancer [16], ovarian cancer [17], and melanoma [18], but functions as a tumor suppressor in colorectal cancer (CRC), and its expression was inversely correlated with prognosis and overall survival [19].